ArticleAsian Pacific journal of cancer prevention : APJCP2025
Health-Related Quality of Life of Non-Small Cell Lung Cancer Patients Treated with Targeted Therapy: Based on the EQ-5D-5L Scale in Vietnam.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Injecting drug use worsens the quality of life in HIV-HCV co-infected patients in Vietnam.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNon-small cell lung cancer (NSCLC) patients can prolong their life owing to targeted therapy. Assessing patients' quality of life (QOL) can help improve QOL and prolong their lives.
methodsA cross-sectional study was conducted at the Department of Medical Oncology 1 and Medical Oncology 2, Vietnam National Cancer Hospital in Tan Trieu, Hanoi, Vietnam, from October 2022 to December 2023 on the basis of the EQ-5D-5L scale to identify the QOL of 310 patients with NSCLC who were treated with first-line targeted therapy. Nonparametric tests and Tobit regression models were used to compare the differences and identify factors related to NSCLC patients' health-state utility.
resultsPain/discomfort (80.6%) and anxiety/depression (75.2%) were the most common dimensions, especially among NSCLC patients experiencing side effects, with only 10.0% of patients reporting no problems. The EQ-5D-5L utility and EQ-VAS scores were 0.8255 and 64.39, respectively. The presence of side effects has been shown to decrease the quality of life for patients (Coef. = -0.04203, p < 0,001). Conversely, support from health insurance has been associated with improved quality of life, with 95% support of health insurance (Coef. = 0.0594, p = 0.001) and 100% support of health insurance (Coef. = 0.0318, p = 0.013) having positive effects.
conclusionHealth insurance support and side effects related to patients' health-state utility scores. Increasing health insurance support and improving side effects would help increase patients' QOL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.